Moon Ja Un, Han Ji Yoon
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Department of Pediatrics, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul 06591, Korea.
Children (Basel). 2021 Nov 29;8(12):1097. doi: 10.3390/children8121097.
Neurodiagnostic investigation requirements are expanding for diagnostic and therapeutic purposes in children, especially in those with developmental delay/intellectual disability (DD/ID). Thus, determination of optimal sedatives to achieve successful sedation and immobility without further neurological compromise is important in children with DD/ID. The purpose of this study is to assess the effectiveness and adverse reactions of chloral hydrate (CH) for brain magnetic resonance imaging (B-MRI) in children with DD/ID compared to those with normal intelligence (NI). We performed a retrospective chart review of children aged from 1 day to 12 years who required elective sedation using CH for B-MRI. About 730 cases (415 with DD/ID and 315 with NI) of CH sedation were conducted for B-MRI. Children with DD/ID showed a higher failure rate (22%) than did those with NI (6%); additional CH and prolonged sedation time were required. There was no difference in incidence of adverse reactions between DD/ID and NI groups ( = 0.338). Older or heavier children with DD/ID ( = 0.036 and = 0.013, respectively), as well as those diagnosed with epilepsy or neuropsychiatric disorders showed higher risk of sedation failure ( < 0.001 for each). In conclusion, CH was a suboptimal sedative drug for children with DD/ID compared with those with NI. Other alternative or supplementary sedatives should be taken into consideration especially for those vulnerable groups.
出于诊断和治疗目的,儿童尤其是发育迟缓/智力残疾(DD/ID)儿童的神经诊断检查需求正在不断增加。因此,对于DD/ID儿童而言,确定能成功实现镇静和制动且不会造成进一步神经功能损害的最佳镇静剂非常重要。本研究的目的是评估与智力正常(NI)儿童相比,水合氯醛(CH)用于DD/ID儿童脑磁共振成像(B-MRI)检查时的有效性和不良反应。我们对年龄在1天至12岁之间、因B-MRI检查需要择期使用CH进行镇静的儿童进行了回顾性病历审查。共对约730例(415例DD/ID儿童和315例NI儿童)进行了CH镇静下的B-MRI检查。DD/ID儿童的失败率(22%)高于NI儿童(6%);需要追加CH剂量并延长镇静时间。DD/ID组和NI组的不良反应发生率无差异(P = 0.338)。年龄较大或体重较重的DD/ID儿童(分别为P = 0.036和P = 0.013),以及被诊断患有癫痫或神经精神疾病的儿童镇静失败风险更高(每项P < 0.001)。总之,与NI儿童相比,CH对于DD/ID儿童而言并非最佳镇静药物。尤其对于那些弱势群体,应考虑使用其他替代或补充性镇静剂。